Dealroom：2025年TechBiox人工智能药物发现报告（英文版）.pdf

After years of proving that data, computation, and biology can accelerate discovery, TechBio companies are now scaling. The era of theory is giving way to execution: platforms deliver pipelines, automation drives reproducibility, and partnerships transition from pilots to multi-step agreements. AI-discovered drug candidates ar经过多年的努力，这些科技生物公司已经证明了数据、计算技术以及生物学方法确实能够加速科研进展。如今，这些企业正在进一步扩大规模。理论研究的时代已经过去，实践应用成为主流：各种技术平台为研究提供了必要的工具，自动化手段确保了实验结果的可重复性，而各种合作模式也正在从初步试点阶段发展为多层次、多阶段的合作关系。那些通过人工智能技术发现的候选药物，已经不再局限于研究阶段，而是正在积极推进临床开发进程。e no longer confined to research, they are now actively advancing into clinical development.